ArticleFrontiers in immunology2025
Identification of MUC5B as a lymph node metastasis-associated gene in lung adenocarcinoma through integrated transcriptomic and machine learning approaches.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Haplotype‑resolved comparison of transcription factor superfamilies between wild and cultivated autotetraploid green jujube and prioritization of candidate transcription factors via machine learning.The plant genome · 2026Article
- Decoding macrophage heterogeneity in the pulmonary fibrosis lung cancer transition.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer, with lymph node metastasis serving as a key prognostic factor. MUC5B, a member of the mucin family, has been implicated in the progression of various cancers, yet its specific role in LUAD metastasis remains underexplored. This study aimed to investigate the role of MUC5B in LUAD progression and its potential as a biomarker for lymph node metastasis. Methods: We integrated TCGA data, single-cell RNA-seq, and machine learning (LASSO, SVM-RFE) to identify MUC5B and associated metastatic markers. A 13-gene predictive model was constructed and validated using ROC analysis. Immunohistochemical staining confirmed the expression of MUC5B in the clinical case samples (n=65). Results: MUC5B was significantly upregulated in LUAD with lymph node metastasis and associated with poor overall and progression-free survival. Knockdown of MUC5B suppressed LUAD cell proliferation, migration, and invasion. The 13-gene model showed high predictive accuracy (AUC > 0.9) for lymph node metastasis. GSVA analysis revealed most model genes correlated positively with Th2 cells and negatively with mast cells, type II interferons. Transcriptomic profiling revealed that MUC5B depletion led to significant downregulation of GINS1, GINS2, and GINS4-core components of the DNA replication GINS complex-suggesting a regulatory axis between MUC5B and cell cycle progression. Enrichment analyses further indicated that MUC5B promotes LUAD metastasis via pathways involved in DNA replication, cell cycle, and metabolic reprogramming. Conclusion: MUC5B facilitates LUAD lymph node metastasis, potentially by regulating the GINS complex and promoting oncogenic signaling. These findings highlight MUC5B as a promising biomarker and therapeutic target for advanced LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.